



16 June 2026

Novartis Pharma AG
Lichtstrasse 35
CH-4056, Basel, Switzerland

Reference:

Novartis Protocol: CPHE885B12201, **EudraCT:** 2021-003747-22, **CTIS:** 2023-507140-37-00

Title: A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma

The results for this trial are posted on CTIS since the trial has been transitioned to CTIS.